GLP-1 drugs shift from obesity treatment to lifestyle use; Merck-Daiichi setback noted

GLP-1 receptor agonists are being repositioned in marketing from medical obesity treatments to lifestyle products for aesthetic and wellness purposes, reflecting a commercial pivot by manufacturers. Separately, a setback for Merck and Daiichi in a drug program is reported, though details are limited. The lifestyle framing could expand demand and alter public-health messaging, but regulatory and reimbursement implications remain uncertain.